Log In Get Started
Press Releases April 5, 2026 08:00 PM

Celestica Q1 2026 Financial Results and Conference Call Tuesday, April 28, 2026

Celestica Announces Q1 2026 Financial Results Release and Conference Call

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
CLS

Celestica Inc. will release its financial results for the first quarter of 2026 after market close on April 27, 2026, followed by a conference call on April 28, 2026. Investors and interested parties can join the live webcast or access a recording afterward.

Celestica Q1 2026 Financial Results and Conference Call Tuesday, April 28, 2026
CLS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Celestica's Q1 2026 financial results will be publicly available on April 27, 2026, after the market closes.
  • The company will host a conference call and webcast the following morning for investor participation.
  • The webcast recording will be accessible on Celestica's official website for those unable to attend live.

TORONTO, April 06, 2026 (GLOBE NEWSWIRE) -- Celestica Inc. (TSX and NYSE: CLS) will release its first quarter 2026 financial results after market close on Monday, April 27, 2026, and will host a conference call at 8:00am ET on Tuesday, April 28, 2026.

Participants are invited to join the live webcast at the following link.

For those unable to participate, a recorded webcast will be available approximately two hours after completion of the call. To access the recorded webcast visit www.celestica.com.

Contact

Celestica Investor Relations
[email protected]


Risks

  • Market reaction to financial results could introduce volatility in the technology and electronics manufacturing sectors.
  • Potential for unforeseen operational or market challenges impacting future financial performance.
  • Dependence on timely dissemination of financial information to maintain investor confidence.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026